Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
RARE
Ultragenyx Pharmaceutical Inc.
Ultragenyx is a rare-disease focused biotech company with approved therapies and a pipeline centered on ultra-rare diseases.
|
$3.49B |
$34.43
-4.97%
|
|
ARQT
Arcutis Biotherapeutics, Inc.
Arcutis' ZORYVE topical PDE4 inhibitor targets inflammatory dermatologic conditions, aligning with Immunology Therapeutics.
|
$3.47B |
$28.66
-1.00%
|
|
LIVN
LivaNova PLC
Directly manufactures/distributes Neuromodulation Devices, including VNS Therapy and proximal hypoglossal nerve stimulation systems.
|
$3.44B |
$63.35
+0.46%
|
|
VCYT
Veracyte, Inc.
The company offers MRD and other liquid biopsy tests, placing it in the liquid biopsy space.
|
$3.42B |
$43.34
-0.44%
|
|
TARS
Tarsus Pharmaceuticals, Inc.
XDEMVY is an FDA-approved ophthalmic drug and core commercial product for Demodex blepharitis.
|
$3.40B |
$78.20
-2.83%
|
|
XENE
Xenon Pharmaceuticals Inc.
Xenon's lead asset XEN1101 is a selective Kv7 potassium channel opener, mapping to Ion Channel Modulators.
|
$3.36B |
$43.38
-0.50%
|
|
FOLD
Amicus Therapeutics, Inc.
Amicus Therapeutics’s marketed products address rare genetic diseases (Fabry and Pompe) and its pipeline includes a rare-kidney disease program (DMX-200 for FSGS), placing it in Biotech - Rare Diseases.
|
$3.35B |
$10.96
+0.74%
|
|
AMED
Amedisys, Inc.
Direct provision of Home Health and Hospice services across multiple centers.
|
$3.31B |
$100.99
|
|
IPGP
IPG Photonics Corporation
IPG markets medical laser systems including thulium lasers for urology, fitting Medical Devices & Biometrics.
|
$3.28B |
$76.34
-1.84%
|
|
GRAL
GRAIL, Inc.
Galleri is a liquid biopsy-based multi-cancer early detection test using cfDNA methylation, the core product.
|
$3.28B |
$86.44
-5.05%
|
|
NAMS
NewAmsterdam Pharma Company N.V.
Lead asset obicetrapib is an oral, small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$3.27B |
$34.73
-1.75%
|
|
UUUU
Energy Fuels Inc.
Radium/radioisotope recovery plans for targeted alpha therapy isotopes (radiopharmaceuticals).
|
$3.23B |
$14.01
-0.07%
|
|
MIRM
Mirum Pharmaceuticals, Inc.
Core business includes liver disease therapeutics, with LIVMARLI and CTEXLI and acquired bile acid medications.
|
$3.22B |
$67.72
+5.65%
|
|
IRON
Disc Medicine, Inc.
Disc Medicine concentrates on rare hematologic diseases (e.g., EPP, Diamond-Blackfan anemia) by targeting iron and heme pathways, with a pipeline centered on rare-disease indications.
|
$3.20B |
$90.45
-1.68%
|
|
VERA
Vera Therapeutics, Inc.
Atacicept is a biologic therapeutic (dual BAFF/APRIL inhibitor) with a monoclonal antibody–like profile, placing Vera's lead program under Monoclonal Antibody Therapeutics.
|
$3.14B |
$48.47
-1.50%
|
|
APLS
Apellis Pharmaceuticals, Inc.
SYFOVRE is an ophthalmic drug (intravitreal) approved for geographic atrophy, representing a direct product Apellis sells.
|
$3.10B |
$25.74
+4.80%
|
|
TVTX
Travere Therapeutics, Inc.
Lead product FILSPARI (sparsentan) is an oral small molecule therapeutic for IgA nephropathy, representing the core commercial and product-focused program.
|
$3.10B |
$35.24
+1.38%
|
|
KNSA
Kiniksa Pharmaceuticals, Ltd.
Kiniksa's core clinical focus centers on immunology therapeutics, driven by ARCALYST and its inflammatory disease pipeline.
|
$3.08B |
$41.27
-0.67%
|
|
PBH
Prestige Consumer Healthcare Inc.
Fleet and other PBH brands address digestive health with OTC solutions.
|
$3.04B |
$61.63
-0.37%
|
|
CGON
CG Oncology, Inc. Common stock
CG Oncology is a biotech company focused on oncology therapies, with cretostimogene grenadenorepvec representing an oncology product in late-stage development.
|
$3.03B |
$37.96
-4.50%
|
|
PRVA
Privia Health Group, Inc.
Privia provides physician enablement, MSO and value-based care services, i.e., Healthcare Services & Facilities.
|
$2.99B |
$23.87
-1.93%
|
|
CPRX
Catalyst Pharmaceuticals, Inc.
CPRX directly develops and sells oral small molecule therapeutics (FIRDAPSE, AGAMREE, FYCOMPA).
|
$2.96B |
$24.38
+0.83%
|
|
LQDA
Liquidia Corporation
Liquidia's YUTREPIA is a PRINT-enabled inhaled treprostinil, a drug-delivery platform that enables high-dose, deep-lung delivery and differentiated pharmacokinetics.
|
$2.94B |
$35.18
+2.90%
|
|
IDYA
IDEAYA Biosciences, Inc.
IDEAYA is a biotechnology company focused on precision oncology therapies (synthetic lethality and ADCs).
|
$2.92B |
$33.87
+1.50%
|
|
TNET
TriNet Group, Inc.
Health Insurance as TriNet provides employee group health benefits to client workforces.
|
$2.92B |
$60.71
+1.00%
|
|
ATEC
Alphatec Holdings, Inc.
Alphatec's primary business is spine/orthopedic implants and devices.
|
$2.92B |
$19.61
-0.48%
|
|
NUVB
Nuvation Bio Inc.
Core oncology focus with IBTROZI and safusidenib as oncology therapies, fitting Biotech - Oncology.
|
$2.91B |
$8.71
+2.35%
|
|
DYN
Dyne Therapeutics, Inc.
Dyne's FORCE platform is a drug delivery platform enabling targeted payload delivery to muscle and CNS, making it a core product category.
|
$2.79B |
$19.45
-0.71%
|
|
SXI
Standex International Corporation
Medical devices & biometrics/public healthcare equipment segment exposure.
|
$2.78B |
$227.25
-1.45%
|
|
BEAM
Beam Therapeutics Inc.
Beam's core offering is a base editing gene therapy platform (DNA editing to correct disease-causing mutations).
|
$2.71B |
$26.75
-0.28%
|
|
VRDN
Viridian Therapeutics, Inc.
Lead programs Veligrotug and VRDN-003 are monoclonal antibodies targeting IGF-1R, i.e., Monoclonal Antibody Therapeutics.
|
$2.70B |
$33.11
+0.24%
|
|
LFST
LifeStance Health Group, Inc.
Direct provider of behavioral health outpatient services (therapy, psychiatric evaluations, care coordination).
|
$2.69B |
$6.84
-1.16%
|
|
SLNO
Soleno Therapeutics, Inc.
Core product category: Soleno's VYKAT XR is an oral small molecule therapeutic (diazoxide choline extended-release) targeting hyperphagia in Prader-Willi Syndrome.
|
$2.65B |
$49.67
-0.55%
|
|
SUPN
Supernus Pharmaceuticals, Inc.
Supernus is focused on CNS/neuropsychiatric drug development with a pipeline spanning ADHD, depression, epilepsy, and Parkinson's disease, including SPN-817, SPN-820, and SPN-443.
|
$2.65B |
$48.49
+2.57%
|
Showing page 9 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
